Last reviewed · How we verify
ketorolac (Acular LS)
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Allergic conjunctivitis, Post-operative ocular inflammation and pain, Corneal refractive surgery pain.
At a glance
| Generic name | ketorolac (Acular LS) |
|---|---|
| Sponsor | Center For Excellence In Eye Care |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, ketorolac reduces the production of prostaglandins, which are key mediators of inflammation, pain, and fever. In the ophthalmic formulation (Acular LS), it penetrates the ocular tissues to provide local anti-inflammatory and analgesic effects in the eye. This mechanism makes it effective for reducing ocular inflammation and pain associated with allergic conjunctivitis, post-operative inflammation, and corneal refractive surgery.
Approved indications
- Allergic conjunctivitis
- Post-operative ocular inflammation and pain
- Corneal refractive surgery pain
Common side effects
- Ocular irritation or stinging
- Headache
- Transient keratitis
- Allergic reactions
Key clinical trials
- Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (PHASE2)
- The Laser in Pseudoexfoliation (LIP) Study (PHASE4)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat (PHASE4)
- Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity (PHASE4)
- Efficacy of Block Injection of an Anti Inflammatory Medicine in Patients With Mandibular Dental Pain (PHASE2)
- Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
- Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |